C
hecklists-important reminders providing much-needed structure in complex environments-are one of the tools recommended to improve patient safety outcomes in the intensive care unit (ICU) (1) . Although checklists have been used to enhance safety in other fields for some time (most notably in the aerospace industry and the military [2] ), their presence in health care has only recently become prominent. Implementation of ICU checklists has been successfully documented at the institutional and state levels (3, 4) ; currently, these initiatives are beginning to gain attention in the lay press (5, 6).
The purpose of this article is to review, discuss, and explain the distinction between quality improvement (QI) and QI research, the controversies surrounding the manner in which QI research is currently conducted, and the role of the Office for Human Research Protections (OHRP) in the structure of these trialsspecifically presenting the recent case of the Keystone Project in Michigan, and the temporary cessation of data collection because of a perceived lack of regulatory evaluation and proper informed consent (IC). In addition, we describe the strong reaction on the Internet to the termination of this project and propose several possible solutions to this research conundrum.
The Keystone Project
Dr. Peter Pronovost and his group at Johns Hopkins have been at the forefront in the academic analysis of the use of checklists in the ICU in an attempt to improve outcomes. Their landmark 2004 study demonstrated that by adding checklists to standard ICU practice, the rate of catheter-related bloodstream infections dropped significantly and remained low (3) . These checklists were an attempt to enhance compliance with an approach recommended by both the Centers for Disease Control and Prevention as well as the Institute for Healthcare Improvement and included the following: hand washing, using full-barrier infection precautions during catheter insertion, cleaning the patient's skin with chlorhexidine, avoiding (whenever possible) the femoral site for line placement, and removing unnecessary catheters in a timely fashion. This project was described as a prospective cohort study with a concurrent control ICU, and the Institutional Review Board (IRB) at the Johns Hopkins Medical Institutions approved the study, with a waiver for IC being granted (3) .
In an analogous-albeit much largerstudy, this same group worked with the Michigan Health and Hospital Association to implement checklists in ICUs throughout that entire state (the Keystone Project). Again, Pronovost was able to demonstrate that the Institute for Healthcare Improvement/Centers for Disease Control and Prevention checklists could be implemented, and their use was associated with a persistent decrease in catheter-related bloodstream infections (and, presumably, saved lives). The Johns Hopkins IRB made a determination that the study would be exempt from IRB evaluation, and IC was waived (4) . Of note, the project was performed without approval from local IRBs (local approval was not sought) as well as in some small hospitals where an IRB did not exist. Administrators in participating Michigan hospitals, however, were aware that this project was happening, as it was approved by (and actually being performed with assistance from) the Michigan Health and Hospital Association. The decisions made by the Hopkins IRB to have the study be exempt from review and not require local IRB approval were (in retrospect) controversial and will be discussed further below.
Checklists in the Lay Press
Approximately 1 year after the Keystone Project results were published, Atul Gawande, MD (a noted Harvard surgeon), wrote a piece entitled "The Checklist" in the December 10, 2007, edition of The New Yorker, focusing on the important, often unrecognized, value of the multidisciplinary critical care team; specifically, he expounded on the manner in which the aforementioned checklists enhance patient safety in the ICU (5). This article garnered significant discussion in both the traditional and the new media (Internet and blogs) (7) (8) (9) (10) (11) .
A mere 3 weeks later, in the December 30, 2007, edition of the New York Times, Dr. Gawande broke yet another story revolving around checklists and patient safety in the ICU: the OHRP had announced the termination of any further data collection involving the Michigan Keystone Project (12) . OHRP claimed that by not obtaining explicit IC from each patient and provider involved in the project, the Hopkins researchers had violated fundamental scientific and ethical research regulations (13, 14) .
With this simple statement, the OHRP sparked significant heated debate, with heels dug in firmly on both sides of the controversy. Numerous academic experts in the field of QI research voiced their opinions throughout the blogosphere, siding with regional and national hospital associations, strongly opining that this ruling was "absurd" and should be changed immediately (7) (8) (9) (10) (11) 15) . Clearly, numerous healthcare organizations were troubled by the potential negative ramifications of this federal action: specifically, concerns were raised that QI projects (both current and future) might be construed as human-subjects research (HuSR) if patient data were collected and actions taken by the result of these data. The wording of a statement from the OHRP in response to numerous letters to the organization did little to alleviate these concerns: "As stated above, the regulations do not apply when institutions are only implementing practices to improve the quality of care. At the same time, if institutions are planning research activities examining the effectiveness of interventions to improve the quality of care, then the regulatory protections are important to protect the rights and welfare of human research subjects . . . " (11, 16) .
Such vague statements continue to fuel the strongly worded, somewhat emotional, academic debate and discourse regarding what, in fact, constitutes QI/ HuSR and what sorts of regulatory protections will be required.
In mid-February 2008, after much pressure from various medical societies, including a letter signed by five medical and nursing organizations (17) , the OHRP came out with another statement, in which their stand on the issue appears to have changed:
"We do not want to stand in the way of quality improvement activities that pose minimal risks to subjects. . . . [OHRP] regulations provide great flexibility and should not have inhibited this activity . . . . Such research would likely have been eligible for both expedited IRB review and a waiver of the informed consent requirement.
. . . the Johns Hopkins project has evolved to the point where the intervention, including the checklist, is now being used at certain Michigan hospitals solely for clinical purposes, not medical research or experimentation. Consequently, the regulations that govern human subjects research no longer apply and neither Johns Hopkins nor the Michigan hospitals need the approval of an IRB to conduct the current phase of the project" (18) .
Although this statement articulated that the current phase of the Keystone Project could resume, the letter stopped short of clarifying the problems that led to the research interruption in the first place and did little to help guide the approval process in the future.
On the surface, the actions taken by the OHRP appear to be understandable: they received a letter of complaint alleging that research was being performed that potentially violated federal regulations; they investigated and discovered that research was, in fact, being performed without IC; finally, Johns Hopkins postponed any further data collection until a full investigation could be completed. There are significant differences, however, between this project and more traditional HuSR, including: 1) the risks to the patient of being in the project (minimal to zero); 2) the risks of not improving compliance with patient safety guidelines (significant); 3) the impracticability of performing IC (both for the patients and potentially the clinicians) given the number of hospitals involved, the necessity of these interventions, and the difficulties of gaining IC in critically ill patients or their surrogates, in general; and 4) the fact that the interventions being performed could have been (some would argue should have been) introduced into clinical practice without either IRB approval or IC. These distinctions are important, and are the primary rationale as to why this kind of QI research should be handled in a different regulatory fashion.
Distinguishing QI from HuSR
Fundamentally, QI is felt to be an integral part of the ongoing management of the system for delivering clinical care, when compared with HuSR, which can be defined as a knowledge-seeking enterprise that is independent of routine medical care (19) . The essential distinction is that QI exists to ensure that patients are receiving a standard of care, whereas the primary focus on HuSR is to find generalizable knowledge and define a new standard of care (20) . Clinicians are under an obligation to perform QI, and it is widely accepted that IC is not necessary. For example, ICUs collect information regarding infection rates, complications, and medication errors-data that are considered confidential and subject to Health Insurance Portability and Accountability Act regulations-all without IC (although much of the data collected in ICUs for QI is deidentified and/or patient identifiers are not included in the data collection process). In general, HuSR does require IC, as participation is voluntary; patients must have the ability to opt out of HuSR if they do not wish to partake.
What is an institution to do when a project has components of both QI and HuSR? Certain thought-leaders feel that such projects should come under the rubric of HuSR and be treated as suchpotentially requiring IC and evaluation by an IRB (19) . Determining when a project is more than just QI and has characteristics of HuSR can sometimes be difficult. Baily and coworkers (19, 20) have made recommendations that a study may be QI/HuSR if it has any of the following qualities: 1) randomization of patients into different intervention groups to enhance confidence in differences obscured by nonrandom selection; 2) testing of issues that are beyond current science and experience, such as new treatments; 3) delayed or ineffective feedback of data from monitoring the implementation of changes; and 4) the involvement in key project roles of researchers who have no ongoing commitment to improvement of the local care situation. It has also been recommended-given many of the differences between traditional HuSR and QI/ HuSR-that institutions consider forming QI-IRBs, with a focused interest in evaluating these sorts of projects (19) .
Once a decision has been made that a project qualifies as QI/HuSR, a significant step is determination of the necessity of IC. Under current regulations, IC can be waived if four conditions are present: 1) the research cannot "practicably be carried out" without the waiver; 2) the subjects' rights and welfare will not be adversely affected; 3) the research involves no more than minimal risk; and 4) subjects will be provided with additional pertinent information after participating. It is beyond the scope of this article to determine when it is "not practicable" to perform a research project without a waiver, and it should be beyond the scope of the principal investigator of a project to define what constitutes "minimal risk" (19) . Federal agencies, such as OHRP, should provide guidance and assist researchers and IRBs with these determinations, in the form of clear, easy-tounderstand, well-structured guidelines.
The crux of the ethical argument has been discussed in two articles recently published in the New England Journal of Medicine by prominent ethicists from the National Institutes of Health, and the Hastings Center (21, 22) : that in the name of protecting patients, the actions of the OHRP may have had the potential to do more harm than good. Both groups came to similar conclusions and provide a rational, logical approach to the ethical and regulatory issues surrounding this case. The first issue that is addressed is as follows: should the Johns Hopkins IRB have deemed the research to be exempt from IRB evaluation. The consensus is that, in fact, it should have undergone review. Both sets of ethicists believe (and it is the opinion of the authors), however, that it would have been more than acceptable from a regulatory and ethical standpoint to have it evaluated in an expedited fashion and that approval from a central IRB such as this would have been sufficient: it was not deemed necessary to get approval from each and every hospital for this particular kind of project.
The second, and clearly more important, issue in this case is the role of IC. Again, with consensus, these prominent bioethicists state that the way to best answer this question is to focus on the purpose of IC: to protect subjects from whatever risks may be inherent in the research project itself. The use of checklists to enhance compliance with agreedupon patient-safety best practices posed no threat to subjects. One author goes so far as to say that this is not to be considered any kind of human subjects research at all; rather, it is to be viewed as a combination of QI and research of organizational function (22) . Regardless of how this kind of research is named (and as the OHRP itself eventually concluded), a waiver of IC appears to be appropriate from an ethical and regulatory standpoint, without putting humans at any risk. Perhaps, if the Hopkins IRB had evaluated the study and provided such a waiver, the OHRP might not have interrupted the Keystone Project. These regulations, however, can often be difficult to interpret. As stated by Baily, "The fact that a sophisticated IRB interpreted the regulations differently from the OHRP is a bad sign in itself. You know you are in the presence of dysfunctional regulations when people cannot easily tell what they are supposed to do" (22) .
Although the risks to the subjects were little to none (and it has been argued that there may have been more of a risk of not being involved in the trial) (21) , the presence of minimal risk should by no means minimize the value and necessity of such research. This field of study-although it is new and still in the process of having the optimal regulatory approaches worked out-is crucial to ensure that national quality-improvement projects have a rigorous, scientific, and evidence-based underpinning.
Conclusion and Recommendations
It is imperative that a middle-ground approach be found for approval of largescale QI/HuSR to prevent laudable projects, such as the Keystone, from being shut down in the future. It is often difficult to generate institutional support for local QI projects, and actions such as those taken by the OHRP will have a chilling effect on these important efforts. Our recommendations include the following: 1) the OHRP must develop new ways to help institutions streamline the approval process of QI/HuSR by designing and developing structured criteria as to what constitutes "impracticability" of protocols without waivers of consent and "minimal risk" to the subjects, as well as providing some guidance for multicenter QI/HuSR projects like Keystone (including an explicit policy for central IRB approval of such projects); 2) more institutions should have formal processes within their IRBs to rapidly and safely evaluate QI/HuSR, with the goal of improving patient safety, making the approval process less onerous and more efficient, while at all times protecting the rights of the individual patient; and 3) hospitals too small to have their own IRBs should be allowed to use IRBs from predetermined designated nearby regional centers of excellence.
Given the intense and impassioned reaction (in the lay press, as well as on blogs throughout the Internet) both to the impressive results shown by Dr. Pronovost's checklist research, as well as the termination of his important project by the OHRP, there is clearly a real demand for large-scale QI/HuSR to proceed-creating new, better standards of care for our hospitalized patients. With a sense of urgency and focused determination, leaders in academia and government must meet to create a structured approach to this kind of research, allowing muchneeded innovation to flourish unimpeded while simultaneously protecting the rights of individual patients.
Hear Dr. Savel interview Dr. Pronovost as part of the 100th icritical care podcast at http://www.sccm.org/podcast is typically associated with hypertrophic cardiomyopathy (1, 2). As systole progresses, the anterior mitral leaflet (AML) is drawn toward the hypertrophied basal ventricular septum. This leads to subaortic stenosis that increases throughout systole producing a characteristic late peaking echo Doppler profile. Independent of hypertrophic cardiomyopathy, left ventricular (LV) hypertrophy and increased cardiac contractility can cause dynamic LVOTO (3-7). Besides being a coincidental phenomenon of academic curiosity, the following situations illustrate the clinically central role played by dynamic LVOTO in critically ill patients. Our institutional review board waived the need for approval for this study.
Report of Patients
Patient 1. A 68-year-old white woman with hypertension, asthma, and rheumatoid arthritis presented to the emergency room with fatigue and dizziness. Dobutamine (5 g/kg/min) was started for hypotension of 80/50 mm Hg. Electrocardiogram (ECG) revealed anterior ST-T changes suggestive of ischemia and troponin I elevation to a peak of 5.1 ng/mL. A grade 3/6 ejection systolic murmur in the left third intercostal space and suspicion of cardiogenic shock lead to a bedside echocardiogram in the emergency room. Two-dimensional imaging revealed overall preserved systolic function with an ejection fraction of 55%, normal LV wall thickness without septal hypertrophy, and systolic anterior motion (SAM) of the chordal apparatus of the AML. Discontinuation of dobutamine, a saline intravenous bolus, and closely supervised administration of 15 mg metoprolol intravenously within 15 minutes reduced the murmur to 1/6 intensity and the LVOTO from 150 to 40 mm Hg. Blood pressure improved to 100/70 mm Hg and cardiac catheterization with coronary angiography confirmed patent coronaries within the hour. An echocardiogram 3 months later showed persistent chordal SAM with peak LVOT gradients of 50 mm Hg. The patient did well clinically on atenolol 100 mg/day with arthritisrelated functional limitations only. A year later, she underwent a lengthy surgery for vertebral fracture stabilization and once again became hypotensive. ECG confirmed LVOTO up to 120 mm Hg and this time she had LV dysfunction, ejection fraction 30% with akinesia of the distal and apical LV segments. She responded to medical management with fluids and intravenous metoprolol once again. The latest echocardiogram 3 months later confirmed normalization of LV function (Fig. 1) . On atenolol 100 mg daily, her resting and stress (dobutamine 50 mcg/kg/min) gradients were 30 and 50 mm Hg, respectively.
Patient 2. A 79-year-old white woman with hypertension and arthritis presented with exertional chest tightness and dyspnea. Vitals were stable and a 3/6 ejection systolic murmur was noted at the left sternal border. ECG showed LV hypertrophy with T inversions and peak troponin I of 0.44 ng/mL (normal Ͻ0.05). Coronary angiography showed luminal irregularities and an 80% lesion in mid- A 76-year-old woman was admitted to the intensive care unit with ischemic cerebrovascular accident and intubation for airway protection. Cardiology was consulted on the 3rd hospital day for new onset tachycardia and hypotension. She was found to be in rapid atrial fibrillation with ventricular rate of about 150/min, blood pressure of 80/50 mm Hg with a 3/6 ejection systolic murmur noted in the left 3rd intercostal space. Troponin was borderline at 0.10 ng/mL (normal Ͻ0.05). Bedside echocardiogram showed SAM of the AML with LVOTO and a peak gradient of 145 mm Hg. Digoxin was discontinued because theoretically its inotropic action could aggravate LVOTO. Intravenous normal saline was initiated totaling 3-4 L/day over the next 3 days along with metoprolol 5 mg intravenously every 4 -6 hours. Hypotension resolved in 1 hour, atrial fibrillation reverted to sinus rhythm spontaneously in 3 hours. LVOTO murmur persisted for two more days. Repeat echocardiogram after 2 weeks showed no evidence for LVOTO.
Patient 5. A 79-year-old white woman was evaluated for new onset systolic murmur with hypotension in the surgical intensive care unit. She had undergone repeated laparotomies for colon cancer and was intubated for airway support on day 21 of hospitalization. Echocardiogram showed a small LV chamber, mild concentric LV hypertrophy, hyperdynamic LV contractility with ejection fraction over 85%. Color Doppler suggested mid- cavity level LV outflow obstruction and pulse wave Doppler confirmed peak gradient of about 40 mm Hg at the mid-cavity level. She responded to intravenous fluids initially. Three days later, she was started on dopamine for hypotension, and murmur increased without clinical improvement. Carefully initiating beta blockers and continued fluid hydration resolved the cardiac issues over the next 3 days.
DISCUSSION
These patients represent only those cases we recognized with dynamic LVOTO developing in the critical care environment (emergency room, surgical, or medical intensive care units). We share these illustrated cases in belief that patients with similar presentations, if recognized early and treated, can have rapid reversal of their hypotension if dynamic LVOTO is the underlying cause. Figure 2 outlines the various underlying conditions and characteristics that may play a role in initiating dynamic LVOTO.
Trauma, bleeding, diuretics-related volume depletion, or any condition that results in a reduction of LV volume could be sufficient to reduce the LVOT area. In patients 4 and 5, prior unrecognized hypovolemia might have contributed to a relative reduction in LV chamber size thereby promoting the Venturi effect, SAM, and increasing the likelihood of LVOTO. Severe emotional stress has been shown to increase serum catecholamine levels substantially in ABS (8, 9) . Approximately, 20% of patients with ABS demonstrate LVOTO (7). Although the mental or physical stress causing ABS is obscure in many instances, the resultant basal hypercontractility likely caused the LVOTO in patients 2 and 3. Acute coronary syndromes involving left anterior descending artery could lead to similar significant dysfunction of the apical segments (5, 10, 11). Basal hypercontractility tries to compensate, and this may cause dynamic LVOTO in some patients with anteroapical infarcts.
Nearly all the commonly used vasopressors for hypotension have significant inotropic effects and possible direct toxicity leading to myocyte damage (12) (13) (14) . When initiated before ensuring adequate volume repletion, this could provide a "double hit"-namely hypercontractility on an already small LV chamberinitiating LVOTO.
Another common combination is the overuse of loop diuretics along with beta agonists in critical care settings to relieve heart failure and bronchospasm (15) . In our experience, a history of hypertension was noted in nearly all the subjects with some concentric hypertrophy. In this substrate, any one of the above insults may be sufficient, but commonly we found several contributors to dynamic LVOTO.
Clinical Recognition. Dyspnea, chest discomfort, and dizziness are the commonest presenting symptoms. Tachycardia is usually present due to the adrenergic excess. Hypotension and ST-T changes in the ECG may suggest acute coronary process (ACS). The only finding that was consistently recognized was the systolic ejection murmur (Table 1 ). The murmur is late peaking and maximally heard in the left 3rd intercostal space. Valsalva usually augments this murmur, whereas handgrip and squatting may reduce the murmur intensity. Figure 3 lists the signs and symptoms that are attributable directly to progressively increasing severity of dynamic LVOTO.
Echocardiography is ideally suited to define the severity of AML SAM, and Doppler analysis quantifies the LVOTO, Figure 4 . Care must be taken to isolate the LVOT Doppler signal from the contamination of a commonly present mitral regurgitation jet. Adjusting the gain settings may at times separate the lower velocity, late peaking dynamic LVOTO Doppler signal from the symmetrical mitral regurgitation jet. Being a variable process, the clinician must ensure echo imaging is done at the time of hearing the murmur. Also, from the systolic blood pressures, peak LV subendocardial wall stress can be indirectly estimated as the sum of the systolic blood pressure and the LVOT gradient. Markedly elevated wall stress may unfavorably shift the oxygen supply-demand curve even in the presence of normal coronary arteries. This acute subendocardial wall stress along with microvascular endothelial dysfunction caused by hypertension (with or without LV hypertrophy), diabetes, hypercholesterolemia, and tobacco use may account for the mild to moderate troponin elevations that we observed.
Cardiac catheterization may still be required to exclude ACS. Catheter pullback from the LV would identify the subaortic location and severity of LVOTO. For ACS to produce enough mid and apical segment dysfunction and compensatory basal hypercontractility to cause LVOTO, the culprit lesion has to be in the proximal-mid left anterior descending coronary artery territory. If significant obstructive coronary artery disease is found, these lesions should be treated aggressively to reduce ischemia and ultimately reverse the dynamic LVOTO.
Management Options. Significant LV dysfunction with an ejection fraction in the 30% range either due to ACS or due to ABS is common in subjects with LVOTO. In this setting, some of the therapies that are commonly initiated for hemodynamic instability like inotropes and intra-aortic balloon may initiate or aggravate LVOTO. In many instances, it may not be possible to differentiate between LVOTO that is caused by apical dysfunction from the coincidental LVOTO that is well known to occur while on inotropes. Frequent auscultation is a cornerstone for diagnosis and treatment as well as correlating echo LVOTO gradients with the clinical situation and reviewing closely the management steps, because presentation may favor one vs. the other as the primary issue. Mitral regurgitation, focal and global LV dysfunction, pulmonary edema, hypotension, and comorbidities interact with LVOTO and each of these needs to be independently addressed to optimize overall outcome. Table 2 outlines the interventions and their mechanism of reducing the LVOTO. Long term, patients should be counseled to avoid dehydration and medical records should list inotropes in allergy section to minimize future indiscriminate use.
Long-Term Prognosis. Dobutamine stress echocardiography literature does not suggest a higher cardiovascular event rate for "incidental" occurrence of LVOTO in the absence of CAD. ABS also seems to have reasonably good prognosis. During dobutamine stress testing, anteroapical akinesia occurred with development of SAM and LVOTO in one instance with normalization of wall motion after SAM resolved. Coronaries were normal and blood pressure response to stress was not hypertensive. Thus, the likely mechanism to explain the transient myocardial "stunning" was sudden increase in wall stress caused by LVOTO. Most of the common cardiac screening tools, catheterization, and even autopsy may miss this diagnosis. We suspect "silent" dynamic LVOTO could account for some of the excess unstable angina, ACS, and even sudden cardiac deaths that occur in women with normal coronaries (5, 10, 11, 15) . Maintenance on long-term beta blockers or calcium channel blockers may help reduce recurrence of this problem. Regular exercise may improve vagal tone and blood pressure management with agents that are known to regress LV hypertrophy may prevent future LVOTO recurrence.
CONCLUSIONS
In the emergency room and in critical care units, dynamic LVOTO occurs more often than is recognized. Although it may sometimes be an "innocent bystander," it may generate severe aortic stenosis type physiology in ventricles that have hitherto not been exposed to such acute preload elevations. Early recognition and appropriate medical management are essential to optimize the clinical outcome in these settings.
